These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29923756)

  • 21. Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis.
    Islam R; Kar S; Ritzén H; Hays A; Tayyem R; Barry C; Keyhani A; Zimmer J; Cruz Caturla M; Couerbe P; Warren M; Khadang A; Bourdage J; Lindley K; Williams D; Hughes N; Sheldon C; Satterwhite C; Vija J; Yu M; Boulay I; Stamatopoulos J; Lin J; Cape S; Estdale S; Thomas E; Dinan A; MacNeill R; Xiao YQ; Garofolo W; Savoie N; Brown M; Rhyne P; Hristopoulos G; Xu A; Goodwin L; Spriggs F; Xu A; Awaiye K; Hayes R; St Charles J; Bouhajib M; DiMarco C; DiMarco L; Savu SR; Bennett P; Kakkanaiah V; Nehls C; Stouffer B; Tabler E; Briscoe C; Karnik S; DuBey I; Kulagina N; Lindsay J; Beaver C; Williard C; Wang H; Feng H; Malone M; Wells E; Fang X; Moussallie M
    Bioanalysis; 2019 Apr; 11(7):645-653. PubMed ID: 30993999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncology biomarkers: discovery, validation, and clinical use.
    Heckman-Stoddard BM
    Semin Oncol Nurs; 2012 May; 28(2):93-8. PubMed ID: 22542316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding assays.
    Stevenson LF; Purushothama S
    Bioanalysis; 2014 Jan; 6(2):185-98. PubMed ID: 24423595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A narrative for bioanalytical method development.
    Tremblay G
    Bioanalysis; 2017 Feb; 9(3):233-234. PubMed ID: 28084801
    [No Abstract]   [Full Text] [Related]  

  • 25. 2017 White Paper on recent issues in bioanalysis: a global perspective on immunogenicity guidelines & biomarker assay performance (Part 3 - LBA: immunogenicity, biomarkers and PK assays).
    Gupta S; Richards S; Amaravadi L; Piccoli S; Desilva B; Pillutla R; Stevenson L; Mehta D; Carrasco-Triguero M; Neely R; Partridge M; Staack RF; Zhao X; Gorovits B; Kolaitis G; Sumner G; Stubenrauch KG; Zou L; Amur S; Beaver C; Berger I; Berisha F; Birnboeck H; Bower J; Cho SJ; Cludts I; Cocea L; Donato LD; Fischer S; Fraser S; Garofolo F; Haidar S; Haulenbeek J; Hottenstein C; Hu J; Ishii-Watabe A; Islam R; Jani D; Kadavil J; Kamerud J; Kramer D; Kurki P; MacMannis S; McNally J; Mullan A; Papadimitriou A; Pedras-Vasconcelos J; Ray S; Safavi A; Saito Y; Savoie N; Fjording MS; Scheibner K; Smeraglia J; Song A; Stouffer B; Tampal N; der Strate BV; Verch T; Welink J; Xu Y; Yang TY; Yengi L; Zeng J; Zhang Y; Zhang Y; Zoog S
    Bioanalysis; 2017 Dec; 9(24):1967-1996. PubMed ID: 29205064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 11th GCC Closed Forum: cumulative stability; matrix stability; immunogenicity assays; laboratory manuals; biosimilars; chiral methods; hybrid LBA/LCMS assays; fit-for-purpose validation; China Food and Drug Administration bioanalytical method validation.
    Islam R; Briscoe C; Bower J; Cape S; Arnold M; Hayes R; Warren M; Karnik S; Stouffer B; Xiao YQ; van der Strate B; Sikkema D; Fang X; Tudoroniu A; Tayyem R; Brant A; Spriggs F; Barry C; Khan M; Keyhani A; Zimmer J; Caturla MC; Couerbe P; Khadang A; Bourdage J; Datin J; Zemo J; Hughes N; Fatmi S; Sheldon C; Fountain S; Satterwhite C; Colletti K; Vija J; Yu M; Stamatopoulos J; Lin J; Wilfahrt J; Dinan A; Ohorodnik S; Hulse J; Patel V; Garofolo W; Savoie N; Brown M; Papac D; Buonarati M; Hristopoulos G; Beaver C; Boudreau N; Williard C; Liu Y; Ray G; Warrino D; Xu A; Green R; Hayward-Sewell J; Marcelletti J; Sanchez C; Kennedy M; Charles JS; Bouhajib M; Nehls C; Tabler E; Tu J; Joyce P; Iordachescu A; DuBey I; Lindsay J; Yamashita J; Wells E
    Bioanalysis; 2018 Apr; 10(7):433-444. PubMed ID: 29701066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Workshop Report: AAPS Workshop on Method Development, Validation, and Troubleshooting of Ligand-Binding Assays in the Regulated Environment.
    Kelley M; Stevenson L; Golob M; Devanarayan V; Pedras-Vasconcelos J; Staack RF; Jenkins R; Booth B; Wakshull E; Bowsher R; Rock M; Dudal S; DeSilva B
    AAPS J; 2015 Jul; 17(4):1019-24. PubMed ID: 25921938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A biomarker assay validation approach tailored to the context of use and bioanalytical platform.
    Hickford ES; Dejager L; Yuill D; Kotian A; Shankar S; Staelens L; Ulrichts H; Lewis S; Louber J; Williams A; Le Provost GS; Cutler P
    Bioanalysis; 2023 Jul; 15(13):757-771. PubMed ID: 37526064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies.
    Valentin MA; Ma S; Zhao A; Legay F; Avrameas A
    J Pharm Biomed Anal; 2011 Jul; 55(5):869-77. PubMed ID: 21530130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A European Bioanalysis Forum recommendation for requiring a context-of-use statement for successful development and validation of biomarker assays.
    Cowan KJ; Kunz U; Blattmann P; Gulati P; Hughes R; Andersen L; Goodman J; Lambert F; Lawrence J; Thwaites D; Golob M; Nelson R; Timmerman P
    Bioanalysis; 2024; 16(16):835-842. PubMed ID: 39101487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 - PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies' inputs on bioanalysis, biomarkers and immunogenicity).
    Neubert H; Olah T; Lee A; Fraser S; Dodge R; Laterza O; Szapacs M; Alley SC; Saad OM; Amur S; Chen L; Cherry E; Cho SJ; Cludts I; Donato LD; Edmison A; Ferrari L; Garofolo F; Haidar S; Hopper S; Hottenstein S; Ishii-Watabe A; Kassim S; Kurki P; Lima Santos GM; Miscoria G; Palandra J; Pedras-Vasconcelos J; Piccoli S; Rogstad S; Saito Y; Savoie N; Sikorski T; Spitz S; Staelens L; Verthelyi D; Vinter S; Wadhwa M; Wang YM; Welink J; Weng N; Whale E; Woolf E; Wu J; Yan H; Yu H; Zhou S
    Bioanalysis; 2018 Dec; 10(23):1897-1917. PubMed ID: 30488729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis.
    Lee JW; Hall M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 May; 877(13):1259-71. PubMed ID: 19038585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker method validation in anticancer drug development.
    Cummings J; Ward TH; Greystoke A; Ranson M; Dive C
    Br J Pharmacol; 2008 Feb; 153(4):646-56. PubMed ID: 17876307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some important considerations for validation of ligand-binding assays.
    Findlay JW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Aug; 877(23):2191-7. PubMed ID: 19022709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fit-for-purpose biomarker immunoassay qualification and validation: three case studies.
    Cowan K; Gao X; Parab V; Nguy T; Wu L; Arron JR; Townsend M; Wallin J; Cheu M; Morimoto A; Wakshull E
    Bioanalysis; 2016 Nov; 8(22):2329-2340. PubMed ID: 27712082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recommendations on biomarker bioanalytical method validation by GCC.
    Hougton R; Gouty D; Allinson J; Green R; Losauro M; Lowes S; LeLacheur R; Garofolo F; Couerbe P; Bronner S; Struwe P; Schiebl C; Sangster T; Pattison C; Islam R; Garofolo W; Pawula M; Buonarati M; Hayes R; Cameron M; Nicholson R; Harman J; Wieling J; De Boer T; Reuschel S; Cojocaru L; Harter T; Malone M; Nowatzke W
    Bioanalysis; 2012 Oct; 4(20):2439-46. PubMed ID: 23157353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addressing the challenges of biomarker calibration standards in ligand-binding assays: a European Bioanalysis Forum perspective.
    Kunz U; Goodman J; Loevgren U; Piironen T; Elsby K; Robinson P; Pihl S; Versteilen A; Companjen A; Fjording MS; Timmerman P
    Bioanalysis; 2017 Oct; 9(19):1493-1508. PubMed ID: 29056059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein biomarker validation via proximity ligation assays.
    Blokzijl A; Nong R; Darmanis S; Hertz E; Landegren U; Kamali-Moghaddam M
    Biochim Biophys Acta; 2014 May; 1844(5):933-9. PubMed ID: 23933049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.